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Abstract
Background: The advantage of hyperfractionated accelerated radiation therapy for advanced head and neck cancer has
been reported. Furthermore, randomized trials and meta-analyses have confirmed the survival benefit of additional
chemotherapy to radiotherapy. We retrospectively analyzed the efficiency and toxicity of the Regensburg standard
therapy protocol "SCHARC" and the overall survival of our patients.
Methods: From 1997 to 2004, 64 patients suffering from advanced head and neck cancer (88 % stage IV, 12 % stage III)
were assigned to receive the SCHARC protocol. Around half of the patients were diagnosed with oro-hypopharynx
carcinoma (52 %), one third with tongue and floor of mouth tumors (29 %) and one fifth (19 %) suffered from H & N
cancer at other sites. The schedule consisted of one therapy block with 30 Gy in 20 fractions over a two week period
with concomitant chemotherapy (d 1–5: 20 mg/m2/d DDP + 750–1000 mg/m2/d 5FU (cont. infusion). This therapy block
was repeated after a fortnight break up to a cumulative dose of 60 Gy and followed by a boost up to 70 Gy (69–70.5
Gy). All patients assigned to this scheme were included in the survival evaluation.
Results: Forty patients (63 %) received both radiation and chemotherapy according to the protocol. The mean follow
up was 2.3 years (829 d) and the median follow up was 1.9 years (678 d), respectively. The analysis of survival revealed
an estimated 3 year overall survival rate of 57 %. No patient died of complications, 52 patients (80 %) had acute grade
2–3 mucositis, and 33 patients (58 %) suffered from acute grade 3 skin toxicity. Leucopenia was no major problem (mean
nadir 3.4 g/nl, no patient < 1.0 g/nl) and the mean hemoglobin value decreased from 13.2 to 10.5 g/dl. Univariate analysis
of survival showed a better outcome for patients with a hemoglobin nadir >10.5 g/dl and for patients who completed the
protocol.
Conclusion: The SCHARC protocol was effective in patients diagnosed with advanced head and neck cancer. It led to
long-term disease control and survival in about 50 % of the patients with significant but acceptable toxicity. Most patients
were not anemic at beginning of therapy. Therefore, we could assess the influence of pre-treatment hemoglobin on
survival. However, a low hemoglobin nadir was associated with poor outcome. This result suggests an influence of anemia
during therapy on prognosis.
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Background
The optimal treatment for head and neck cancer is still a
matter of dispute. In resectable tumors, complete resec-
tion followed by adjuvant radio- or radiochemotherapy
revealed excellent local control rates but survival is
impaired by second malignancies and distant metastases
[1]. However, in advanced, non resectable head and neck
cancer, local tumor control still predicts the outcome.
Therefore, many approaches have aimed at reducing the
rate of local treatment failures [2].
Rationale of the SCHARC treatment regimen
The application of hyperfractionated accelerated radiation
therapy for advanced head and neck cancer has been
shown to be of major advantage in comparison to nor-
mofractionated schedules or accelerated radiation therapy
alone [3]. In addition, randomized trials and meta-analy-
ses have confirmed the survival benefit of additional
chemotherapy to radiotherapy. Moreover, some authors
recommend radiochemotherapy followed by surgical
resection of the reduced tumor masses [4-6].
Split course radiotherapy in standard fractionation
schemes is known to be disadvantageous for patients with
head and neck cancer. However, the detrimental effect of
a pause can be compensated by accelerated hyperfraction-
ation [3]. Ernst-Stecken et al. recently reported encourag-
ing results in a phase II study on hyperfractionated
accelerated split course radiochemotherapy in head and
neck cancer [7]. This study revealed a remarkable local
control rate of 78 % and an overall survival rate of 49 %
after a 3 year observation period. A comparable treatment
regimen was also established as the Regensburg standard
protocol "SCHARC" from 1997 to 2004.
Prognostic significance of hemoglobin level of cancer 
patients
Recently, strong evidence has been found concerning the
role of anemia and tumor oxygenation as prognostic fac-
tors [8-12]. Some studies with hypoxic cell sensitizers or
tumor oxygenation modification protocols reported an
improved survival rate [13,14]. Anemia is the most impor-
tant cause of tumor hypoxia. Therefore, it is not surprising
that anemia can influence the prognosis of cancer
patients. Anemia during therapy (hemoglobin nadir) is
worth to be considered as a prognostic factor because it
frequently is a consequence of the therapy modality (sur-
gery, chemotherapy). Correcting anemia with transfu-
sions and application of erythropoietin therefore seems to
be a valid approach to compensate for the negative effects
of anemia. However, in a current randomized trial correc-
tion of anemia with erythropoietin did not result in sur-
vival benefit. Hence, erythropoietin should be
administered with care and only within a study.
We retrospectively analyzed the local efficiency and toxic-
ity of the Regensburg standard therapy protocol
"SCHARC" and the overall survival of our patients. This
protocol was not a study protocol but a protocol for
patients not encompassed in any study whatsoever. Addi-
tionally, we investigated the role of protocol deviations
and anemia as potentially relevant factors for the overall
survival.
Methods
From 1997 to 2004, 64 patients suffering from advanced
head and neck cancer (88 % stage IV, 12 % stage III) were
assigned to receive the SCHARC protocol at the Depart-
ment of Radiation Oncology at the University of Regens-
burg. All patients had been considered as inoperable by a
board of ENT-surgeons and radiation oncologists and
were without any contraindications against the treatment
scheme. The patients had been considered as inoperable
due to tumor location, size, and extension or because of
comorbidities. The patients were on average 56 (± 8) years
old and mostly of male gender (see Table 1). Most
patients (58 %) had a history of combined alcohol and
nicotine abuse. 9 % were non smokers, 17 % had no alco-
hol abuse in their anamnesis and 3 % of the patients had
neither a history of alcohol nor nicotine abuse. About half
of the patients were diagnosed with oro-hypopharynx car-
cinoma (52 %), one third with tongue and floor of mouth
tumors (29 %) and one fifth (19 %) suffered from head
and neck cancer at other sites (Table 1).
The staging included clinical examination, CT or MRI
scan, ultrasound of the neck and upper endoscopy by the
head and neck surgeon with biopsies of the tumor
regions.
66 % of the tumors were classified as T4. 24 % and 10 %
were categorized as T3 and T2 tumors, respectively. 15 %
were staged as N3 and 65 % were classified as N2. Only 9
% and 11 % were categorized as N1 and N0 (Table 1).
According to the UICC (1992) classification 88 % of the
patients were stage IV and 12 % stage III.
Prior to start of therapy a percutaneous endoscopically
controlled gastrostomy (PEG) was given to all patients. All
patients gave informed consent to the treatment.
Radio- and Chemotherapy
The PTV (planning target volume) included the primary
tumor region and the regional lymphatic drainage of the
neck. All patients were planned with a computer aided
3D-planning system (different versions (4.0–6.1) of the
Helax TMS™). The common technique were two lateral
isocentric opposed portals for the cranial part of the PTV
combined with an anterior or two anterior/posterior
opposed portals for the caudal part of the PTV (includingBMC Cancer 2006, 6:279 http://www.biomedcentral.com/1471-2407/6/279
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a midline absorber if reasonable). After 39 Gy the spinal
cord was shielded and the posterior neck nodes were
treated with 9–12 MeV electron beam up to 60 Gy. The
radiotherapy was given with 6 MeV photons by a Siemens
Linear Accelerator (Primus) with MLC's.
The schedule consisted of one therapy block with 30 Gy in
1.5 Gy twice a day over a two week period with concomi-
tant chemotherapy (d 1–5: 20 mg/m2/d DDP + 750–1000
mg/m2/d 5FU (cont. infusion)). This therapy block was
repeated after a fortnight break up to a cumulative dose of
60 Gy and followed by a boost up to 70 Gy (69–70.5 Gy).
Assessment of Toxicity
The acute toxicity was usually classified according to the
CTC criteria [16]. Patients were seen once a week and skin
and mucosa toxicities were documented in the chart. In 5
% of patients the grade of mucosal toxicity was not docu-
mented according to CTC criteria. At least once a week
complete blood cell count and kidney associated parame-
ters (creatinin, electrolytes) were checked. Late toxicity
was classified according to the LENT-SOMA scale [17].
Definition of protocol violation
Application of Mitomycin C (n = 4) and Carboplatin (n =
4) instead of DDP (due to limited renal function) was
considered a protocol violation. No or incomplete hyper-
fractionation (n = 11) due to skin toxicities or strongly
deteriorated general condition was also considered a
major protocol deviation. 4 patients discontinued the
therapy. The additional application of folic acid (n = 4)
was not considered as a protocol violation (minor devia-
tion).
Statistics
Overall survival was defined as the time interval from the
start of radiochemotherapy to either the date of death
(event) or to the date of last contact with the patient. Free-
dom from local treatment failure (FLTF) was defined as
the time interval from radiochemotherapy to either the
date of recurrence (event) or to the date of last contact
with the patient or to the date of death. First follow-up
examination was done by the head and neck surgeons and
the radiation oncologists 6 weeks after ending of therapy.
The standard procedure of the first follow up examination
included CT or MRI scan, ultrasound of the neck and
upper endoscopy with biopsy of suspicious areas. The
head and neck surgeon examined the patients every three
months by means of upper endoscopy and ultrasound of
the neck. These intervals were increased to six months
after two years of follow-up. Radiotherapy follow-up was
performed twice a year in the first two years and once a
year after the second year.
Patients were grouped by pre-therapy hemoglobin value
and hemoglobin nadir to assess for the influence of
hemoglobin on the survival probability. We used the
median pre-treatment hemoglobin level of 12.5 g/dl as
the cut off value for the pre-treatment analysis and the
median of hemoglobin nadir of 10.5 g/dl as the cut off
point for the analysis during treatment. The median
hemoglobin values were used as cut off points to obtain
two approximately equal sized patient groups.
The possible influence of other factors leading to a drop in
hemoglobin values, such as weight loss or deteriorated
general condition was not analysed and can therefore not
be ruled out. Overall survival and FLTF probability were
Table 1: Demographic and tumor related parameters of the 64 
patients.
Patients' characteristics
Parameter No. %
Age (years)
Median (mean ± SD) 55 (56 ± 8)
Range 38 – 71
Gender
Male 55
Female 9
Tumor site
Oral cavity 19 30
Nasopharynx 5 8
Oro-/Hypopharynx 34 53
Larynx 6 9
T-category
T1 0 0
T2 6 9
T3 16 25
T4 41 64
Tx 1 2
N-category
N0 7 11
N1 6 9
N2 35 54
N3 8 13
Nx 8 13
Grading
G1 2 3
G2 44 69
G3 17 27
Gx 1 2
UICC-stage
III 8 13
IV 56 87BMC Cancer 2006, 6:279 http://www.biomedcentral.com/1471-2407/6/279
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estimated by means of Kaplan Meier analysis using the
Cox-proportional hazards regression model. We used the
commercially available WinSTAT®  for Microsoft®  Excel
Version 1999.2 software for data analysis.
Results
Outcome
The three years overall survival rate was 57 % for all
patients (intention to treat analysis, Fig. 1) and 68 % for
those patients who were treated without protocol viola-
tion (Fig. 2). The patients with protocol modifications
showed a significantly (p = 0.02) worse outcome com-
pared to those without modifications. The three years
overall survival rate for these patients was only 39 % (Fig.
2).
Stratified by means of the pre-therapy hemoglobin value
(cut off: 12.5 g/dl (median)) we found no influence of
hemoglobin on survival probability (p = 0.97). Stratified
using the hemoglobin nadir (cut off: 10.2 g/dl (median))
we found a significant influence of hemoglobin on sur-
vival probability (3 years OSR of 70 % vs. 38 %, p < 0.01,
Fig. 3).
Locoregional recurrences occurred in 15 patients and 6
patients developed distant metastases. The estimated
probability of freedom from local treatment failure (FLTF)
and the metastases free survival rate were 60 % and 84 %
at three years, respectively.
Acute toxicity
Grade III skin toxicity with intensive erythema and conflu-
ent moist desquamation was found in 53 % of patients
and in 47 % grade II toxicity was observed (Table 2). Dur-
ing therapy most patients suffered from intensive mucosi-
tis. Mucositis was staged as grade II and III in 50 % and 42
% of the patients, respectively. 5 % of the patients devel-
oped a grade I mucositis. In 3 % of patients no grading of
mucositis was performed (Table 2). Acute grade II – III
dysphagia was very frequent (76 %). Mild or no dysphagia
(grade 0-I) was exceptional (8.5 %). In 8.5 % of patients
no data on the grade of dysphagia were available. 20 % of
the patients developed pathological creatinin values dur-
ing therapy (CTC grade 1–2), 78 % had no pathological
creatinin values during therapy and in one patient (2 %)
creatinin data were not available. Hematological toxicity
was relatively low (Table 2). Only 1 patient had a hemo-
globin level below 8 g/dl and 7 patients had leukocyte
counts of >2 – 1 × 109/l (CTC grade III) during therapy.
No grade IV toxicity was observed in any of the 64
patients. After completion of therapy all patients were
asked how they had tolerated therapy. One patient evalu-
ated the tolerance as very good, 24 patients stated that
they tolerated the therapy well (43 %), 24 (43 %) consid-
ered tolerance as moderate and 7 (13 %) patients stated
that they tolerated therapy badly (n = 2) or very badly (n
= 5).
Late toxicity
The leading symptoms of late radiation toxicity were dry-
ness of mouth and changes in taste. 92 % of patients
reported a moderate to complete dryness of mouth.
Slightly (grade I – II) and markedly (grade III) altered taste
was observed in 50 % and 7 % of the patients, respec-
tively. 43 % of the patients had no change of taste. Grade
I and II hoarseness was found in 28 % and 5 % of patients,
Kaplan Meier Analysis of survival probability Figure 2
Kaplan Meier Analysis of survival probability. Comparison 
between patients who completed the SCHARC-scheme (n = 
40, black line) and patients with modified therapy (n = 24, 
blue line). The Cox regression analysis showed a statistically 
significant difference between the groups (p = 0.01).
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Kaplan Meier Analysis of survival probability of all 64 patients  assigned for the SCHARC-scheme (intention to treat analy- sis) Figure 1
Kaplan Meier Analysis of survival probability of all 64 patients 
assigned for the SCHARC-scheme (intention to treat analy-
sis).
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respectively. 67 % of the patients had no problems with
speech in the course of the follow up time.
Discussion and Conclusion
The presented analysis revealed fairly good survival data
obtained from patients treated with the SCHARC scheme
and an influence of hemoglobin nadir on prognosis.
Outcome and toxicities, the Regensburg data versus a 
previously published phase II study
Recently, Ernst-Stecken et al. published the results of a
phase II study encompassing patients treated from 1991
to 2002 with a comparable scheme of split course hyper-
fractionated radio-chemotherapy with 5-FU and DDP [7].
Because this and our study used a very similar treatment
schedule, it is important to compare the study results of
both investigations. We achieved a three year overall sur-
vival rate of 57 % compared to 53 % in the study of Ernst-
Stecken et al. [7]. The local recurrence and metastasis free
survival rates were also similar to our study with 60 % and
84 % versus 77 % and 73 %. The skin toxicity and the
degree of mucositis were more intense than in the refer-
ence study [7]. We estimated 58 % of the patients skin
reactions and 42 % of mucositis as grade III whereas the
corresponding values of the reference study were 18 %
and 13 %, respectively [7]. This discrepancy is explained
by the tendency to overestimate the grade of side effects in
clinical routine and the more critical approach how a
patients sequelae should be scored within a study.
Another reason could be that supportive care was different
between the institutions. Interestingly, the patients esti-
mated their therapy tolerance as good or moderate in 86
% of cases and only in 14 % as bad or very bad.
In spite of notable toxicity we were able to reproduce the
remarkable survival data of Ernst-Stecken et al. which
were also comparable to other studies assessing curative
treatment in advanced head and neck cancer
[2,3,7,18,19].
Hemoglobin nadir as a prognostic factor
Anemia is a major cause of tumor hypoxia influencing not
only radiosensitivity of tumor cells but also triggering irre-
versible changes in tumor biology [8,20-26]. A strong cor-
relation of polarographically measured pO2 to uPA-levels
in tissue of head and neck cancer was described recently
[26]. The enzyme uPA is a VEGF-dependent factor
involved in the degradation of the extracellular matrix and
neovascularization. It has also been described as a predic-
tor for metastatic spread and aggressiveness in breast can-
cer [26-28]. VEGF itself not only stimulates vascular
proliferation and angiogenesis it also plays a key role in
tumor invasion and metastatic tumor spread [29-31].
Dunst et al. found that hemoglobin values below 11 g/dl
are predictive for upregulation of VEGF-levels in cancer
patients as well as in patients without cancer [32]. Moreo-
ver, Becker et al. described a significant influence of severe
anemia (below 11 g/dl) on tumor oxygenation [8].
Table 2: Acute toxicity according common toxicity criteria (CTC) classification ((Trotti et al., 2000).
Intensity grade 0–1 2 3 4 no grade
Acute toxicity (CTC)
Mucositis 3 (5 %) 32 (50 %) 26 (41 %) 0 (0 %) 3 (5 %)
Skin (including erythema and epitheliolysis) 0 (0 %) 30 (47 %) 34 (53 %) 0 (0 %) 0 (0 %)
Anemia (nadir) 34 (53 %) 22 (34 %) 1 (2 %) 0 (0 %) 7 (11 %)
Leucopenia 32 (50 %) 16 (25 %) 7 (11 %) 0 (0 %) 9 (14 %)
Kaplan Meier analysis of survival probability Figure 3
Kaplan Meier analysis of survival probability. Comparison 
between patients with hemoglobin nadir above 10.2 g/dl (n = 
28, red line) and patients with a hemoglobin nadir below 10.2 
g/dl (n = 28, black line). The Cox regression analysis showed 
a statistically significant difference between the groups (p < 
0.01).
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However, we found no prognostic significance of pre-
treatment hemoglobin values (p = 0.97). This finding
contrasts the results of other authors and our previously
published data [12]. The lack of prognostic significance of
pre-treatment hemoglobin concentration might partly be
explained by the fact that only 5 % of our patients had ini-
tial hemoglobin values below 11 g/dl which is considered
to be the threshold for severe anemia in head and neck
cancer. In our previous study in 1998, the percentage of
patients with hemoglobin values below 11 g/dl was
higher [12] (approx. 11 %, unpublished data). However,
the hemoglobin concentration fell below the threshold of
11 g/dl [8] during therapy and reached a median value of
10.2 g/dl (nadir). Patients developing hemoglobin values
below 10.2 g/dl in the course of therapy progressed signif-
icantly worse than those with higher hemoglobin concen-
trations (p = 0.01). This finding indicates that severe
anemia during oncologic therapy influences the survival
rate of head and neck cancer patients. The biological con-
sequences of anemia therefore depend more on the
hemoglobin level than on the time of measurement.
Moreover, a correction of low hemoglobin levels could
not revert the biological changes induced by anemia. This
might be one reason why transfusions and erythropoietin
applications were less effective as expected [15]. There-
fore, severe anemia should be avoided during the com-
plete course of therapy.
Implications of Split course Schemes
Overall treatment time is known to be a predictor of out-
come in head and neck cancer [15]. Therefore, it is
strongly recommended to avoid intermissions during
radio- or radiochemotherapy. Split course radiotherapy in
standard fractionation schemes is known to be detrimen-
tal for head and neck cancer patients. However, the disad-
vantage of a pause can be compensated by accelerated
hyperfractionation [3]. In this case, overall treatment time
is not prolonged compared to normofractionated sched-
ules. In a recent study, patients representing a selected
group with unfavorable risk factors such as bad general
condition, concurrent diseases or advanced tumors were
treated with a 2 × 2.1 Gy split course schedule and Carbo-
platin [33]. Despite high daily doses this treatment
scheme was considered feasible and the unfavorable sur-
vival rates were accounted for negative selection [33]. In a
further meta-analysis by Budach et al. no advantage but
also no disadvantage was found for hypo-fractionated
split course schemes in comparison to normofractionated
treatment schemes with the same dose as long as the total
treatment time was identical [3].
However, even though some aspects of intermissions are
negative others might be positive. One the one side, we
fear proliferation or repopulation of tumor cells during a
split. It is estimated that this effect reduces the isoeffective
dose up to 0.6 Gy per day [3,34,35]. On the other hand we
hope for reoxygenation of the tumor to enhance radiosen-
sibility. Some authors measured an increased pO2 level
after a fortnight break but this is not a proof of reoxygen-
ation [36-39].
The addition of chemotherapy can also help to compen-
sate possible negative effects of split course regimens.
Moreover, it is hardly feasible to apply such aggressive
combination of radio- and chemotherapy without a
planned or unplanned pause. This pause enables normal
tissue to recouperate and furthermore reduces the acute
non hematologic toxicity. Therefore, when combining
accelerated hyperfractionation with "poly-chemotherapy"
a defined pause at a defined dose can be justified. This is
confirmed by the results of our and the study of Ernst-
Stecken et al. [7]. The three years overall survival rates of
both studies were above 50 % in spite of nearly 90 % of
UICC stage IV patients.
Due to various reasons, 38 % of the patients planned for
treatment according to the SCHARC protocol received a
somewhat differing treatment. In contrast to prospective
studies with clearly defined inclusion and exclusion or
break off criteria, an increased willingness to modify our
clinic specific treatment scheme to reduce therapy-associ-
ated morbidity existed. However, it is unclear if the
observed worse prognosis in the modified treatment
scheme was due to the change of therapy or an epiphe-
nomenon caused by negative selection.
We therefore conclude that the SCHARC regimen seems
highly effective in spite of a high rate of T4 (64 %) and
stage IV patients. Despite promising data the significance
of split course RCT in SCCHN is unclear. It therefore
seems justifiable to analyse the benefit of this scheme in a
randomised, prospective study. Moreover, we found an
influence of hemoglobin nadir on the prognosis.
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